O
Ofer Nativ
Researcher at Technion – Israel Institute of Technology
Publications - 210
Citations - 5937
Ofer Nativ is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Renal cell carcinoma & Nephrectomy. The author has an hindex of 36, co-authored 206 publications receiving 5474 citations. Previous affiliations of Ofer Nativ include Mayo Clinic & Rappaport Faculty of Medicine.
Papers
More filters
Journal ArticleDOI
MicroRNAs accurately identify cancer tissue origin
Nitzan Rosenfeld,Ranit Aharonov,Eti Meiri,Shai Rosenwald,Yael Spector,Merav Zepeniuk,Hila Benjamin,Norberto Shabes,Sarit Tabak,Asaf Levy,Danit Lebanony,Yaron Goren,Erez Silberschein,Nurit Targan,Alex Ben-Ari,Shlomit Gilad,Netta Sion-Vardy,Ana Tobar,Meora Feinmesser,Oleg Kharenko,Ofer Nativ,Dvora Nass,Dvora Nass,Marina Perelman,Marina Perelman,Ady Yosepovich,Ady Yosepovich,Bruria Shalmon,Bruria Shalmon,Sylvie Polak-Charcon,Sylvie Polak-Charcon,Eddie Fridman,Eddie Fridman,Amir Avniel,Isaac Bentwich,Zvi Bentwich,Dalia Cohen,Ayelet Chajut,Iris Barshack,Iris Barshack +39 more
TL;DR: The effectiveness of miRNAs as biomarkers for tracing the tissue of origin of cancers of unknown primary origin is demonstrated and the utility of the miRNA biomarkers by quantitative RT-PCR is validated.
Journal ArticleDOI
Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules
Morad Nakhleh,Haitham Amal,Raneen Jeries,Yoav Y. Broza,Manal Aboud,A'laa Gharra,Hodaya Ivgi,Salam Khatib,Shifaa' Badarneh,Lior Har-Shai,Lea Glass-Marmor,Izabella Lejbkowicz,Ariel Miller,Samih Badarny,Raz Winer,John P.M. Finberg,Sylvia Cohen-Kaminsky,Frédéric Perros,David Montani,Barbara Girerd,Gilles Garcia,Gérald Simonneau,Farid Nakhoul,Shira Baram,Raed Salim,Marwan Hakim,Maayan Gruber,Ohad Ronen,Tal Marshak,Ilana Doweck,Ofer Nativ,Zaher Bahouth,Da-you Shi,Wei Zhang,Qing-Ling Hua,Yue-Yin Pan,Li Tao,Hu Liu,Amir Karban,Eduard Koifman,Tova Rainis,Roberts Skapars,Armands Sivins,Guntis Ancans,Inta Liepniece-Karele,Ilze Kikuste,Ieva Lasina,Ivars Tolmanis,Douglas W. Johnson,Stuart Z. Millstone,Jennifer Fulton,John W. Wells,Larry H. Wilf,Marc Humbert,Marcis Leja,Nir Peled,Hossam Haick +56 more
TL;DR: An artificially intelligent nanoarray based on molecularly modified gold nanoparticles and a random network of single-walled carbon nanotubes for noninvasive diagnosis and classification of a number of diseases from exhaled breath could contribute to one of the most important criteria for successful health intervention in the modern era.
Journal ArticleDOI
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.
Karim Bensalah,Allan J. Pantuck,Nathalie Rioux-Leclercq,Rodolphe Thuret,Francesco Montorsi,Pierre I. Karakiewicz,Nicolas Mottet,Laurent Zini,Roberto Bertini,Laurent Salomon,A. Villers,Michel Soulié,Laurent Bellec,Pascal Rischmann,Alexandre de la Taille,R. Avakian,Maxime Crepel,Jean Marie Ferriere,Jean-Christophe Bernhard,Thierry Dujardin,Frédéric Pouliot,Jérôme Rigaud,Christian Pfister,B. Albouy,Laurent Guy,Steven Joniau,Hendrik Van Poppel,Thierry Lebret,T. Culty,Fabien Saint,Amnon Zisman,Orit E. Raz,Herve Lang,Romain Spie,Andreas H. Wille,Jan Roigas,Alfredo Aguilera,Bastien Rambeaud,Luis Martinez Pineiro,Ofer Nativ,Roy Farfara,François Richard,Morgan Rouprêt,Christian Doehn,Patrick J. Bastian,Stefan C. Müller,Jacques Tostain,Arie S. Belldegrun,Jean Jacques Patard +48 more
TL;DR: PSM status occurs more frequently in cases in which surgery is imperative and is associated with an increased risk of recurrence, but PSM status does not appear to influence cancer-specific survival.
Journal ArticleDOI
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Tom J.H. Arends,Ofer Nativ,Massimo Maffezzini,Ottavio De Cobelli,Giorgio Canepa,F. Verweij,Boaz Moskovitz,Antoine G. van der Heijden,J. Alfred Witjes +8 more
TL;DR: CHT is an option for BCG therapy as adjuvant treatment for intermediate- and high-risk papillary NMIBC and appears to be safe and has higher 24-mo recurrence-free survival thanBCG therapy.
Journal ArticleDOI
The Role of a Combined Regimen With Intravesical Chemotherapy and Hyperthermia in the Management of Non-muscle-invasive Bladder Cancer: A Systematic Review
Rianne J.M. Lammers,J. Alfred Witjes,Brant A. Inman,Ilan Leibovitch,Menachem Laufer,Ofer Nativ,Renzo Colombo +6 more
TL;DR: C-HT may become standard therapy for high-risk patients with recurrent tumors, for patients who are unsuitable for radical cystectomy, and in cases for which bacillus Calmette-Guérin treatment is contraindicated.